Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post‐Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by Klotho
Journal of the American Heart Association · 17.02.2026 · 15 (4)
DOI: 10.1161/jaha.125.045175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 17.02.2026. Verfasst von Sara Vázquez-Sánchez und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cardiorenal Translational Laboratory, Imas12 Research Institute Hospital Universitario 12 de Octubre Madrid Spain. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Glucuronidase, Myocardium, Kidney. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Elevation of FGF23 (fibroblast growth factor 23) and decreased Klotho levels have been associated with various cardiovascular and renal diseases. However, the combined study of the FGF23–Klotho axis in ischemic heart disease remains elusive.
Methods
We analyzed the associations between circulating FGF23 and Klotho levels with cardiac and renal parameters, as well as mortality outcomes following myocardial infarction (MI). Cardiac tissue from patients with ischemic heart disease and a post‐MI mouse model were analyzed to assess myocardial FGF23 expression. Proteomic analysis was performed to examine myocardial pathways activated by FGF23 and regulated by Klotho.
Results
We observed an inverse correlation between circulating levels of FGF23 and Klotho in patients after MI. Elevated plasma FGF23 levels were particularly associated with ST‐segment–elevation MI and cardiac dysfunction, including reduced left ventricular ejection fraction, prolonged corrected interval, and higher Killip–Kimball classification of cardiac risk, identifying FGF23 as a potential prognostic marker of overall and cardiac‐related mortality. In contrast, systemic Klotho levels were reduced in patients with ST‐segment–elevation MI but did not correlate with mortality. In cardiac tissue, ischemic injury significantly upregulated FGF23 expression. Although Klotho prevented FGF23‐induced proteomic alterations, it did not inhibit cardiac FGF23 overexpression in the post‐MI model.
Conclusions
FGF23 represents a promising biomarker for mortality and cardiac dysfunction in patients with MI. Although Klotho does not appear to be a reliable predictor of mortality after MI, its cardioprotective properties suggest a role in modulating FGF23‐driven metabolic, structural, and proliferative processes in the myocardium.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiorenal Translational Laboratory, Imas12 Research Institute Hospital Universitario 12 de Octubre Madrid Spain.
- RICORS2040-Renal, ISCIII Madrid Spain.
- Acute Cardiac Care Units, Cardiology Service Hospital Universitario Puerta de Hierro-Majadahonda Madrid Spain.
- Department of Vascular Physiopathology Hospital Nacional de Paraplejicos, SESCAM Toledo Spain.
- Department of Vascular Physiopathology Hospital Nacional de Paraplejicos, IDISCAM Toledo Spain.
- Clinical and Invasive Cardiology Group, Instituto de Investigación Sanitaria del Hospital La Paz (IdiPAZ) Hospital Universitario La Paz Madrid Spain.
ORCID-Profile: Sara Vázquez-Sánchez, Ana Blasco, Marina Polo-Salguero, Laura Mourino-Álvarez, Marta Gil-Fernández, Nerea Corbacho-Alonso, José Alberto Navarro-García, Elisa Mercado-García, Laura González-Lafuente, Elena Rodríguez-Sánchez, Daniel González-Moreno, Alberto Pérez-Gómez, Jesús Vázquez, Juan Antonio López, María G Barderas, Gema Ruiz-Hurtado
Zitieren
APA
Vázquez-Sánchez, S., Blasco, A., Polo-Salguero, M., Mourino-Álvarez, L., Gil-Fernández, M., Corbacho-Alonso, N., Navarro-García, J. A., Mercado-García, E., González-Lafuente, L., Rodríguez-Sánchez, E., González-Moreno, D., Pérez-Gómez, A., Matutano, A., Vázquez, J., López, J. A., Fernández-Velasco, M., Barderas, M. G., & Ruiz-Hurtado, G. (2026). Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post‐Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by Klotho. Journal of the American Heart Association, 15(4). https://doi.org/10.1161/jaha.125.045175
Vancouver
Vázquez-Sánchez S, Blasco A, Polo-Salguero M, Mourino-Álvarez L, Gil-Fernández M, Corbacho-Alonso N, et al. Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post‐Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by Klotho. Journal of the American Heart Association. 2026;15(4). doi:10.1161/jaha.125.045175
BibTeX
@article{VzquezSnchez2026,
author = {Vázquez-Sánchez, Sara and Blasco, Ana and Polo-Salguero, Marina and Mourino-Álvarez, Laura and Gil-Fernández, Marta and Corbacho-Alonso, Nerea and Navarro-García, José Alberto and Mercado-García, Elisa and González-Lafuente, Laura and Rodríguez-Sánchez, Elena and González-Moreno, Daniel and Pérez-Gómez, Alberto and Matutano, Andrea and Vázquez, Jesús and López, Juan Antonio and Fernández-Velasco, María and Barderas, María G and Ruiz-Hurtado, Gema},
title = {Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post‐Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by Klotho},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {4},
doi = {10.1161/jaha.125.045175}
}
EUVIMED